Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1569
http://purl.obolibrary.org/obo/NCIT_C1569
|
|---|---|
| Preferred Name | Daclizumab |
| Definitions |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
|---|---|
| prefLabel | Daclizumab
|
| label | Daclizumab
|
| PDQ_Closed_Trial_Search_ID | 42006
|
| code | C1569
|
| prefixIRI | NCIT:C1569
|
| in_subset |
See more
See less
|
| Display_Name | Daclizumab
|
| Preferred_Name | Daclizumab
|
| FDA_UNII_Code | CUJ2MVI71Y
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Daclizumab
|
| CAS_Registry | 152923-56-3
|
| NSC Number | 725173
|
| NCI_Drug_Dictionary_ID | 42006
|
| Legacy Concept Name | Daclizumab
|
| type | |
| ALT_DEFINITION | A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42006
|
| Accepted_Therapeutic_Use_For | Kidney transplant rejection, prevention
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C0663182
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |